GRI Bio shares are trading lower. The company announced that the FDA has granted Orphan Drug Designation to GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis.

Benzinga Newsdesk www.benzinga.com Positive 83.9%

Neg 0% Neu 0% Pos 83.9%

Comments

No comments yet. Be the first!